Partnering & Outsourcing Editorial

  1. How TissueTech Managed Growth, Virtual Trials, And Survived COVID-19 8/11/2020

    Since its inception in 1997, TissueTech has been a pioneer in the clinical application of human birth tissues. In July 2020 the company announced the initiation of the first of two Phase 3 clinical trials. To complete those trials, the company knew it had to grow its internal capabilities. It did so by investing heavily in the expansion of its clinical and manufacturing programs.

  2. The First Controlled Clinical Trial For A CRISPR Enhanced Bacteriophage Therapy 6/29/2020

    Several companies are working on bacteriophage therapies, using natural bacteriophage isolated from the environment. Those treatments use the cell’s machinery to create new virus particles that burst out of the cell, killing it in the process and infecting other cells. Locus Biosciences has demonstrated that the CRISPR-Cas3 mechanism makes crPhage significantly more effective at killing target bacteria than their natural counterparts. 

  3. Virtual DIA 2020: Regulators, Patients, Technology, And Networking 5/13/2020

    COVID-19 has disrupted lives around the world. The trade show industry, which has been critical to knowledge sharing, networking, and relationship-building has also been significantly impacted by travel restrictions and responsible social distancing practices. Even the DIA Global Annual Meeting, the largest industry gathering in the clinical and regulatory space, has announced it will be a virtual event. 

  4. Regeneron’s COVID-19 Trial Reaches Patients In 5 Days 5/12/2020

    AdventHealth’s most serious COVID-19 patients were in the ICU and needed immediate help. When it learned about a clinical trial being conducted by Regeneron Pharmaceuticals, it acted quickly. “We were able to get this trial up and running in a record period of time,” states Dr. Steven Smith. “We signed the documents with Regeneron and were administering the drug to our patients in less than five days.” 

  5. An Outsourcing Model Built To Survive Pandemics 4/21/2020

    Drug sponsors put a lot of time and effort into developing their outsourcing model. Unfortunately, a host of unforeseen issues can cause any well-planned strategy to veer off the rails. Accent Therapeutics had the foresight to implement an outsourcing model that allows it to avoid unforeseen operational pitfalls., which helped it minimize disruptions from the COVID-19 pandemic.

  6. Overcome The Challenge Of Moving From Pre-Clinical To Clinical 4/16/2020

    Kymera Therapeutics will face two main challenges in advancing its product pipeline. The first relates to making the move from animal testing to trials in humans. The second is choosing the right targets. For any company introducing a new platform, there is a universe of targets that can be pursued. 

  7. COVID-19 And Its Impact On Clinical Trials 4/10/2020

    Debora Araujo, founder and CEO of ClinBiz, recently hosted a live online discussion on the COVID-19 pandemic and the impact it will have on clinical trials. The purpose of the call was to share knowledge of how the pandemic might impact clinical trials and what sponsor companies can do to adapt. 

  8. Amid COVID-19, Clinical Trials Must Go On 4/8/2020

    The COVID-19 pandemic continues to impact economies around the world, and many businesses and activities have been curtailed or shut down. Others, however, must continue to move forward. Clinical trials fall into the latter category.

  9. Clinical Study Risk Management During The COVID-19 Pandemic 4/6/2020

    While COVID-19 has proven to be an extremely trying obstacle for the life science community, it is crucial for organizations to not only focus on the short-term impacts of COVID-19 but on developing a long-term plan of action for how we return to business once the pandemic subsides.

  10. Adaptimmune Enters Uncharted Waters With SPEARHEAD-1 Trial 4/2/2020

    I recently spoke to Adaptimmune CEO Adrian Rawcliffe to learn more about the company’s pipeline in its entirety, the ongoing SPEARHEAD-1 trial, and being at the forefront of cell therapy trials.